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ABSTRACT The renin-angiotensin system plays a criti-
cal role in sodium and fluid homeostasis. Genetic or acquired
alterations in the expression of components of this system are
strongly implicated in the pathogenesis of hypertension. To
specifically examine the physiological and genetic functions of
the type 1A receptor for angiotensin II, we have disrupted the
mouse gene encoding this receptor in embryonic stem cells by
gene targeting. AgtrIA(-/-) mice were born in expected
numbers, and the histomorphology of their kidneys, heart,
and vasculature was normal. AT1 receptor-specific angioten-
sin II binding was not detected in the kidneys of homozygous
AgtrlA(-/-) mutant animals, and AgtrlA(+/-) heterozy-
gotes exhibited a reduction in renal AT1 receptor-specific
binding to "50% of wild-type [AgtrIA(+/+)] levels. Pressor
responses to infused angiotensin II were virtually absent in
AgtrlA(-/-) mice and were qualitatively altered in
AghIA(+/-) heterozygotes. Compared with wild-type con-
trols, systolic blood pressure measured by tail cuff sphygmo-
manometer was reduced by 12 mmHg (1 mmHg = 133 Pa) in
AgtrlA(+/-) mice and by 24 mmHg in AgtrlA(-/-) mice.
Similar differences in blood pressure between the groups were
seen when intraarterial pressures were measured by carotid
cannulation. These studies demonstrate that type 1A angio-
tensin II receptor function is required for vascular and
hemodynamic responses to angiotensin II and that altered
expression of the AgtrlA gene has marked effects on blood
pressures.
The renin-angiotensin system (RAS) is one of the primary
physiological regulators of sodium and fluid balance (1). The
RAS regulates body-fluid homeostasis through several distinct
mechanisms-including effects on hemodynamics and vascular
tone, direct stimulation of sodium reabsorption by the kidney,
and stimulation of aldosterone production by the adrenal
glands (2). The propensity of the RAS to cause elevated blood
pressure was first recognized in acquired disorders such as
renovascular hypertension (3), and alterations in the activity of
this system have been strongly implicated in the pathogenesis
of essential hypertension. For example, variations in genes
encoding renin (4, 5), angiotensinogen (6, 7), angiotensin-
converting enzyme (8, 9), and angiotensin receptors (10-12)
have been associated with hypertension in human populations
and in animal models of sodium-sensitive hypertension.
The major biologically active product of the RAS is the
multifunctional peptide angiotensin 11 (1). The physiological
effects of angiotensin II are elicited through binding to specific
cell-surface receptors (13). Angiotensin II receptors belong to
the large family of rhodopsin-like G protein-associated recep-
tors and have been divided into two pharmacologically distinct
types designated type 1 (AT1) and type 2 (AT2) (13-17). AT1
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receptors are thought to mediate the known functions of
angiotensin 11 (13-15); they are defined pharmacologically by
their high-affinity binding to the nonpeptide antagonist losar-
tan (Dup 573). AT2 receptors exhibit high-affinity binding to
the antagonists PD 123177 and CGP 42112, but the physio-
logical function of and signaling mechanisms used by AT2
receptors are not known (13, 16, 17).
Among the AT1 receptors, two subtypes ATlA and ATlB
have been identified in human, rat, and mouse (18-21). These
receptors are products of separate genes, share substantial
sequence homology, and have wide tissue distributions. The
ATlA receptor seems to predominate in most tissues except the
adrenal gland and the anterior pituitary (18-26), and expres-
sion of ATlA and ATlB receptors may be differentially regu-
lated in the heart and the adrenals (22, 25, 26). This differential
tissue distribution and regulation of AT1 receptor subtypes
may serve to modulate the biological effects of angiotensin II.
However, due to the lack of discriminatory pharmacological
antagonists, the individual functions of the two AT1 receptor
subtypes (A and B) have not been defined.
Associations between alterations in AT1 receptor-encoding
genes and hypertension have been identified in previous
studies. For example, Deng and associates (10, 11) found that
the AT1l receptor gene is in a region of rat chromosome 2 that
has an effect on blood pressure in both Lyon and Dahl rats. The
same group found no association between the ATlA receptor
locus and hypertension in Dahl rats (27). However, in a recent
study in humans with essential hypertension, Bonnardeaux et
at (12) identified an association between several ATIA recep-
tor-encoding gene polymorphisms and hypertension. Thus,
there are data from humans and rats suggesting that AT1
receptor genes might play a role in the pathogenesis of
hypertension. In the present study, we have used gene targeting
to determine which distinct physiological functions are specific
to the ATlA receptor gene. We have also defined the potential
for naturally occurring mutations of the ATlA receptor gene to
affect the regulation of blood pressures.
MATERIALS AND METHODS
Gene Targeting. The gene encoding the AT1A receptor
(AgtrJA) was isolated from an E14TG2a embryonal stem cell
(28) genomic library, using a probe generated by PCR from
primers synthesized on the basis of published sequences for the
rat ATlA receptor (15). A restriction map of the genomic clone
is shown in Fig. 1A. To construct the targeting vector, shown
in Fig. 1B, a 0.5-kb EcoRI fragment containing coding se-
quences from the AgtrlA gene was replaced by the neomycin
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resistance cassette (neo) from pMClneopolA (29). The Herpes
simplex thymidine kinase gene from pMClTK was inserted
downstream of the 3' homology arm. The embryonic stem cell
line BK4, a subclone isolated from E14TG2a, was electropo-
rated with the linearized targeting vector followed by positive-
negative selection (29) with G418 at 0.15 mg/ml and 2 ,uM
ganciclovir. G418/ganciclovir-resistant colonies were ex-
panded and analyzed by PCR (30). Targeted embryonal stem
cell lines were identified by the presence of a 1.7-kb PCR
product using the PCR primers indicated by the arrows in Fig.
1C.
Blastocyst Injection and Mouse Genotype Analysis. Tar-
geted embryonal stem cell lines containing the disrupted
AgtrlA gene were injected into blastocysts to generate male
chimeras, which were then mated with inbred females of strain
C57BL/6J. F1 progeny heterozygous for the disrupted AgtrlA
gene were interbred to generate F2 animals. To determine
animal genotypes, genomic DNA was purified from tail biop-
sies, digested with BamHI, and analyzed by Southern blot
analysis. Incorporation of the targeting vector into the locus
introduces another BamHI site, so that the targeted allele can
be identified by the presence of a diagnostic 3.8-kb BamHI
fragment using the probe shown in Fig. 1C. A representative
autoradiogram of a Southern blot analysis of tail DNA samples
is shown in Fig. 1D.
[Sarl,Ile8]Angiotensin II Receptor Autoradiography. Kid-
neys were removed from anesthetized AgtrlA(+/+), (+/-),
and (-/-) mice, placed in liquid plastic (OCT compound),
and frozen in isobutane chilled by liquid nitrogen. Twenty-
micrometer sections were thaw-mounted on glass slides, and
receptor autoradiography was done as described (31) with
some modifications. Tissue sections were incubated with 200
pM 125I-labeled [Sarl,lle8]angiotensin II in buffer alone or in
the presence of 5 ,uM concentrations of [Sari,1le8]angiotensin
II (DuPont/NEN), PD 123319 (provided by D. Taylor, Parke-
Davis, Ann Arbor, MI) (AT2 receptor antagonist), Dup 753
(provided by R. Smith, DuPont/Merck, Wilmington, DE)
(AT, receptor antagonist), or a combination of Dup 753 and
PD 123319. After multiple washes, the sections were dried and
exposed to Hyperfilm ,max (Amersham) for 3 days. Prints
were made from the autoradiograms using F5 Kodabromide
paper (Eastman Kodak).
Angiotensin II Infusions. Mice were anesthetized with
isoflurane. Flexible plastic catheters (0.015 i.d.; Norton, Ak-
ron, OH) were placed in the carotid artery and jugular vein.
The catheters were tunneled under the skin and exteriorized
posteriorly at the base of the neck. After allowing the animals
at least 4 hr to recover from anesthesia, arterial blood pressure
was measured under unrestrained conditions by an investigator
(C.F.B.) who did not know the genotypes of the animals. Pulse
wave forms were monitored and recorded at a rate of 200
samples per sec through the carotid catheter using Windaq
data acquisition and playback software (Dataq Instruments,
Akron, OH). After an adequate baseline recording was estab-
lished, angiotensin II at 10 ,tg/kg was administered as an i.v.
bolus, and mean arterial pressures were recorded continu-
ously. Mean pressures were calculated at 20-sec intervals for 10
min after the administration of angiotensin II.
Blood Pressure Measurements. Systolic pressure was mea-
sured in conscious mice using a computerized noninvasive tail
cuff system that determines tail blood flow using a photoelec-
tric sensor. The validity of this system and its correlation with
intraarterial pressure measurements have been demonstrated
(32). Consistent with these previous studies, there was a
significant linear correlation between blood pressure mea-
sured by tail cuff and by intraarterial catheter within our
present experiments (correlation coefficient = 0.68; P <
0.0001). All blood pressure determinations were obtained by
an investigator (C.F.B.) who was unaware of the genotypes of
the animals being tested. Mice were trained to the tail cuff
apparatus for at least 5 days. Blood pressures were then
measured and recorded for 5 consecutive days, and a mean
value was generated for each individual mouse. To obtain
intraarterial pressures, carotid artery catheters were placed as
described above. After the animals had recovered from anes-
thesia, they were maintained in a quiet environment, unre-
strained and conscious, and blood pressure was recorded
continuously over a period of 30 min. Based on the blood
pressure recordings during this period, a mean value for
systolic pressure was calculated by using the Windaq software
package (Dataq Instruments).
Statistical Analysis. Data are presented as the means ±
SEMs. Statistical significance was assessed by using analysis of
variance and the unpaired t test.
RESULTS AND DISCUSSION
Gene Targeting. After introduction of the targeting plasmid
(Fig. 1B) into embryonic stem cells by electroporation, colo-
nies resistant to G418 and ganciclovir (29) were screened for
homologous recombinants by PCR. Targeting was confirmed
by Southern blot analysis using the probe shown in Fig. 1C. The
targeting frequency was -1 per 100 doubly resistant colonies.
Four male chimeras that were mated with C57BL/6 females
transmitted the disrupted AgtrlA gene to their progeny pro-
ducing (129 x C57BL/6)F1 mice heterozygous (+/-) for the
mutation. These F1(+/-) heterozygotes were interbred to
generate F2 mice that were homozygous for the mutant ATIA
receptor gene.
Generation of Mice That Lack ATlA Receptors. Previous
studies have suggested that the RAS plays a role in fetal
development and organogenesis. This hypothesis is based, in
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FIG. 1. Strategy for disrupting the AgtrlA gene. (A) Endogenous
ATIA receptor-encoding locus. The intronless coding region is indi-
cated by the black box. (B) Targeting construct. neo, Neomycin
resistance cassette; TK, thymidine kinase. (C) Structure of the dis-
rupted gene. The PCR primers, the lengths of diagnostic restriction
fragments, and the probe used for Southern analysis are shown. B,
BamHI; Bg, Bgl II; and R, EcoRI. (D) Southern blot of offspring of an
AgtrlA(+/-) X AgtrlA(+/-) cross. An 8.6-kb BamHI fragment
indicates the wild-type allele, and a 3.8-kb fragment identifies the
targeted locus.
3522 Genetics: Ito et at
Proc. NatL Acad Sci USA 92 (1995) 3523
part, on the observation that there is programmed expression
of both AT1 and AT2 receptors within the developing fetus
(33-36). To determine the relative survival of animals with the
disrupted AgtrlA gene, we analyzed 20 F1 x F1 matings
yielding 152 weanlings. The proportion of animals of each
genotype conformed to Mendelian expectations: 39 (+/+), 77
(+/-), and 36 (-/-); this is in marked contrast with our
observation that most mice homozygous for a targeted dis-
ruption of the angiotensinogen locus (Agt) die before weaning
(37). The kidneys of adult AgtrlA(-/-) mice were normal;
this again contrasts with surviving Agt(-/-) adults that have
distinctive renal histological abnormalities characterized by
arteriolar wall thickening and focal areas of renal cortical
atrophy (37). The survival and normal renal histomorphology
ofAgtrlA(-/-) animals suggest that the marked detrimental
effects of angiotensinogen deficiency are not caused by the
absence of signaling through the ATIA receptor; they may
result from the lack of ATlB receptor- or AT2 receptor-
mediated responses or from the absence of other peptides that
are generated from angiotensinogen (38).
Angiotensin II Binding in Mutant Mice. To define the
contribution of ATlA receptors to angiotensin II binding, we
performed receptor autoradiography with 1251-labeled
[Sar1,Ile8]angiotensin II. Fig. 2 shows that both AT1 receptor-
and AT2 receptor-specific binding could easily be detected in
the kidneys of (+/+) animals: AT1 receptor binding (Fig. 2C)
is distributed in cortical areas and around glomeruli; AT2
receptor binding (Fig. 2D) is also present in the cortex but
extends into the medulla with a vascular and/or tubular
distribution. In the kidneys of AgtrlA(-/-) mice, total an-
giotensin II binding (Fig. 2F) is significantly reduced compared
with controls (Fig. 2A) and consists almost entirely of AT2
receptor-specific binding (Fig. 2I). AT1 receptor-specific bind-
ing (Fig. 2H) is virtually absent in AgtrlA(-/-) mice, con-
1+7+1 l
firming the efficacy of the gene disruption and suggesting that
most AT1 receptor-specific binding in the kidney is due to
binding to ATlA receptors. Heterozygous (+/-) mice have
levels of AT1 receptor-specific binding intermediate between
the (-/-) and (+/+) animals (data not shown); thus, absence
of a singleAgtrlA allele results in a substantial reduction in the
binding level that is not compensated through other regulatory
mechanisms.
In Vivo Responses to Angiotensin II. To determine the
effects of altered ATlA receptor expression on in vivo re-
sponses to angiotensin II, we infused angiotensin II peptide i.v.
to conscious mice (Fig. 3). In (+/+) mice, an i.v. 10 jig/kg
bolus of angiotensin II causes an initial increase in blood
pressure that peaks at 20 sec followed by a delayed depressor
response. Despite the reduced level of receptor expression in
AgtrlA(+/-) mice, the magnitudes of the peak pressor and
depressor effects of angiotensin II seen in these heterozygotes
resembled those in AgtrlA(+/+) animals. However, the pat-
tern of the response was qualitatively different: the positive
pressor response was short-lived in the AgtrlA(+/-) mice
compared with controls, and the depressor response was
clearly evident within 400 sec inAgtrlA(+/-) mice compared
with >500 sec in AgtrlA(+/+) animals. This result suggests
that the character of the pressor-depressor responses medi-
ated by angiotensin II can be altered when receptor density is
reduced. Infusions of angiotensin II had virtually no effect on
the blood pressures ofAgtrlA(-/-) mice, demonstrating that
this acute hemodynamic response to angiotensin II requires
ATlA receptors.
Blood Pressures inAgtrlA Mutant Mice. We determined the
steady-state effects of changes in ATlA receptor expression on
blood pressures in F2 animals between 8 and 12 weeks of age.
The three genotypes differed significantly (Fig. 4): compared
withAgtrlA(+/+) controls, systolic blood pressures measured
FIG. 2. [Sar1,Ile8]Angiotensin II receptor autoradiography in kidneys fromAgtrlA(+/+) (A-E) and AT1A(-/-) (F-J) mice.A andF show total
125I-labeled [Sar1,lle8]angiotensin II binding; it is substahtially reduced in the AgtrIA(-/-) kidney (F). B and G show binding in the presence of
excess concentrations of unlabeled [Sar1,11e8]angiotensin II, which results in complete displacement of radioligand. C and H show binding of
125I-labeled [Sar1,Ile8]angiotensin II in the presence of the AT2 receptor antagonist PD 123319. Residual radioactivity represents AT1
receptor-specific binding; it is virtually absent in the AgtrlA(-/-) mouse (H). D and I show 1251-labeled [Sarl,lle8]angiotensin II binding in the
presence of the AT1 receptor antagonist losartan (Dup 753). Residual radioactivity represents AT2-specific binding; it is present in both the
AgtrlA(+/+) (D) and AgtrlA(-/-) kidneys (I). E and J depict 125I-labeled [Sarl,lle8]angiotensin II binding in the presence of a combination of
PD 123319 and losartan. The levels of residual radioactivity are not different from the levels of nonspecific binding seen in B and G.
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FIG. 3. Effects of an i.v. bolus of angiotensin II at 10 ,ug/kg on
blood pressure in conscious mice. Changes in mean arterial pressure
at 20-sec intervals after angiotensin II infusion are depicted for
AgtrlA(+/+) (n = 7), (+/-) (n = 9), and (-/-) (n = 6) animals.
Data are presented as the means ± SEMs.
by tail cuff (Fig. 4A) were reduced by 12 mmHg in
AgtrlA(+/-) mice [P = 0.011 versus (+1+)] and by 24 mmHg
in AgtrlA(-/-) mice [P < 0.0001 versus (+/+) and P =
0.0013 versus (+/-)]. When intraarterial pressures were mea-
sured by carotid cannula, similar relative differences were
observed: arterial pressures were reduced by 17 mmHg in
(+/-) mice [P = 0.026 versus (+/+)] and by 43 mmHg in
(-/-) mice compared with controls [P = 0.0003 versus (+/+)
andP = 0.02 versus (+/-)]. Thus, there is a direct relationship
between blood pressures and expression of the AgtrlA gene.
Even a partial reduction in expression has a demonstrable
effect, and this effect is seen in animals with all of their
homeostatic mechanisms otherwise intact.
Exclusion of the Effects of Linked Genes. To be certain that
the differences in blood pressures observed in AgtrlA mutant
mice do not depend on genes linked to the AgtrlA locus that
differ in mouse strains 129 and C57BL/6, we also examined
blood pressures in F1(+/+) and F2(+/-) mice. These animals
differ systematically in having either a wild-type or a mutant
ATIA gene derived from strain 129, but they do not differ
systematically in any other genes, linked or unlinked to the
AgtrlA locus. Blood pressures were measured by tail cuff
sphygmomanometer. Systolic blood pressures in the F2(+/-)
mice (n = 7) were significantly lower than in the F1(+/+)
animals (n = 9) [103 ± 3 mmHg versus 111 ± 6 mmHg; P =


























FIG. 4. Effect of the ATlA receptor mutation on systolic blood
pressure measured by tail cuff (A) and systolic blood pressure mea-
sured by intraarterial catheter (B). Data are presented as the means ±
SEMs [*, P = 0.011 versus (+/+); **, P < 0.0001 versus (+/+), and
P = 0.0013 versus (+/-); §, P = 0.026 versus (+/+); 1, P = 0.0003
versus (+ / +), and P = 0.02 versus (+/-) by analysis of variance and
unpaired t test].
pressure are independent of any other genetic differences
between strain 129 and C57BL/6 mice, linked or unlinked to
the AgtrlA locus.
Conclusions. In these studies, we have examined the phys-
iological functions of the ATlA receptor for angiotensin II
using gene targeting. We find that the ATjA receptor is not
necessary for normal development and survival and that the
heart, kidney, and vascular system appear normal in the
absence of ATlA receptors. ATIA receptors are, however,
required for both the pressor and depressor hemodynamic
responses to exogenous angiotensin II infusion, and virtually
all of the AT1 receptor-specific angiotensin II binding in the
kidney is due to ATlA receptors. AgtrlA(+/-) heterozygotes
have reduced levels of receptor expression that is not com-
pensated through other regulatory mechanisms. The reduced
receptor density in AgtrlA(+/-) mice results in a qualitative
alteration in the pressor response to angiotensin II and is
associated with a significant reduction in resting blood pres-
sure. Blood pressure is further reduced inAgtrlA(-/-) mice.
These studies demonstrate the importance of the AgtrlA gene
in regulating blood pressure in mice and suggest that variants
of the humanAGTRIA gene, which alter its level of expression,
may likewise affect blood pressures.
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